Iqvia
IQVIA, formerly known as Quintiles IMS, is a leading global provider of advanced analytics, technology solutions, and contract research services for the healthcare industry. Headquartered in the United States, IQVIA operates extensively across North America, Europe, and Asia, delivering insights that drive healthcare innovation. Founded in 2016 through the merger of Quintiles and IMS Health, IQVIA has quickly established itself as a pivotal player in the life sciences sector. The company offers a unique blend of data analytics, real-world evidence, and technology solutions, enabling clients to navigate the complexities of drug development and market access. With a strong market position, IQVIA is recognised for its comprehensive suite of services, including clinical trial management, commercialisation support, and data-driven insights. Its commitment to leveraging cutting-edge technology and deep industry expertise has earned it numerous accolades, solidifying its reputation as a trusted partner in the healthcare ecosystem.
DitchCarbon Score
How does Iqvia's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Iqvia's score of 67 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Iqvia's reported carbon emissions
In 2023, IQVIA reported total greenhouse gas emissions of approximately 526,198,000 kg CO2e, comprising 8,221,000 kg CO2e from Scope 1, 28,714,000 kg CO2e from Scope 2, and a significant 481,928,000 kg CO2e from Scope 3 emissions. This represents a decrease from 2022, where total emissions were about 464,574,000 kg CO2e. IQVIA has set ambitious climate commitments, aiming for a 55.1% absolute reduction in Scope 1 and 2 emissions by 2030, using a 2019 baseline. Additionally, the company targets a 90% reduction in total emissions across all scopes by 2050. These targets align with the Science Based Targets initiative (SBTi) and are designed to support the global effort to limit warming to 1.5°C. The company also commits to reducing Scope 3 emissions from business travel by 55% per full-time equivalent (FTE) by 2030 and ensuring that 70% of its suppliers by emissions will have science-based targets by 2027. IQVIA's long-term strategy includes a comprehensive plan to achieve net-zero emissions by 2050, reflecting its commitment to sustainability and environmental responsibility in the pharmaceutical and biotechnology sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2012 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 43,577,000 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 48,394,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 45,222,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Iqvia is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
